Drug Approval | August 27, 2024
Merck receives EC approval for Winrevair for treatment of PAH
Winrevair is the first activin signaling inhibitor therapy for PAH approved in Europe
Winrevair is the first activin signaling inhibitor therapy for PAH approved in Europe
Higher revenues backed by huge demand and expanding network contributed to the growth in bottom line
The tele-icu services which had a soft launch four months ago have already provided valuable assistance to 250+ patients in some of the remotest villages in India
The company reported total income at Rs. 509.8 crore in Q1 FY25 as compared to Rs. 570.3 crore in Q1 FY24
The product is bioequivalent and therapeutically equivalent to the reference listed drug
The drug will be manufactured at the group's formulation manufacturing facility in Ahmedabad SEZ - II, India
Selexipag is a prostacyclin receptor agonist indicated for the treatment of pulmonary arterial hypertension
Dyslipidemia is a critical risk factor for cardiovascular diseases
Azilsartan Medoxomil and Chlorthalidone Tablets had annual sales of US$ 77.9 mn in the United States (IQVIA MAT March 24).
35,000 doctors from across India pledged their support for the initiative to raise awareness about cardiovascular diseases
Subscribe To Our Newsletter & Stay Updated
